BioNexus Gene Lab logo
BGLC logo

BioNexus Gene LabNasdaqCM:BGLC Stock Report

Market Cap US$7.3m
Share Price
n/a
1Y-7.4%
7D15.4%
Portfolio Value
View

BioNexus Gene Lab Corp.

NasdaqCM:BGLC Stock Report

Market Cap: US$7.3m

BGLC Stock Overview

Through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. More details

BGLC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BioNexus Gene Lab Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioNexus Gene Lab
Historical stock prices
Current Share PriceUS$0.41
52 Week HighUS$3.39
52 Week LowUS$0.21
Beta1.6
1 Month Change45.69%
3 Month Change8.03%
1 Year Change-7.39%
3 Year Change-98.04%
5 Year Changen/a
Change since IPO-91.72%

Recent News & Updates

Recent updates

BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

Feb 14
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable

Shareholder Returns

BGLCUS Trade DistributorsUS Market
7D15.4%-2.6%-0.9%
1Y-7.4%9.0%22.6%

Return vs Industry: BGLC underperformed the US Trade Distributors industry which returned 13% over the past year.

Return vs Market: BGLC underperformed the US Market which returned 24.3% over the past year.

Price Volatility

Is BGLC's price volatile compared to industry and market?
BGLC volatility
BGLC Average Weekly Movement23.3%
Trade Distributors Industry Average Movement5.8%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: BGLC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BGLC's weekly volatility has decreased from 44% to 23% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201730Lee Tanwww.bionexusgenelab.com

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing.

BioNexus Gene Lab Corp. Fundamentals Summary

How do BioNexus Gene Lab's earnings and revenue compare to its market cap?
BGLC fundamental statistics
Market capUS$7.28m
Earnings (TTM)-US$941.56k
Revenue (TTM)US$9.26m

0.8x

P/S Ratio

-7.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGLC income statement (TTM)
RevenueUS$9.26m
Cost of RevenueUS$8.01m
Gross ProfitUS$1.25m
Other ExpensesUS$2.19m
Earnings-US$941.56k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.052
Gross Margin13.47%
Net Profit Margin-10.17%
Debt/Equity Ratio0.2%

How did BGLC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 03:57
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioNexus Gene Lab Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution